Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity

Ewelina Kluza*, Sin Yuin Yeo, Sophie Schmid, Daisy W. J. Van der Schaft, Renate W. Boekhoven, Raymond M. Schiffelers, Gert Storm, Gustav J. Strijkers, Klaas Nicolay

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Tumor-associated inflammation has been recognized as an important tumor growth propagator and, therefore, represents an attractive target for anti-cancer therapy. In the current study, inspired by recent findings on the anti-tumor activity of liposomal glucocorticoids, we introduce paramagnetic and fluorescent liposomes, encapsulating prednisolone phosphate (PLP), to evaluate the local delivery of liposomal glucocorticoids to the tumor and its importance for the therapeutic response. The new multifunctional liposomes (Gd-PLP-L) (120nm diameter, 5.8mg PLP/60?mol lipid, bioexponential blood-clearance kinetics (T(1/2?)=2.4?0.5h, T(1/2?)=42.0?12.4h), drug leakage of 15%/72h (in vitro)), containing 25mol% Gd-DTPA-lipid and 0.1mol% of rhodamine-lipid, were tested in B16F10 melanoma subcutaneously inoculated in C57BL/6 mice, and compared to the original PLP formulation (PLP-L). A single dose of Gd-PLP-L (20mgPLP/kg/week, i.v.) was found to significantly inhibit tumor growth compared to non-treated mice (P
Original languageEnglish
Pages (from-to)10-17
JournalJournal of Controlled Release
Issue number1
Publication statusPublished - 10 Apr 2011


  • Anti-tumor therapy
  • Tumor-associated inflammation
  • Multifunctional liposomes
  • Magnetic resonance imaging
  • Monitoring of drug delivery

Cite this